Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on July 21, 2026. The report discloses corporate governance changes effective as of July 20, 2026, specifically regarding the expansion of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size to six members.
- New Appointment: R. Todd Plott, M.D., was appointed to the Board to serve until the 2026 annual meeting of stockholders.
- Committee Assignment: Dr. Plott was appointed to the Board's Governance Committee.
- Qualifications: Dr. Plott is a board-certified dermatologist with over 30 years of experience in dermatologic care, research, and innovation, and is a former FDA advisory committee member.
Guidance, Outlook, and Risks
Compensatory Arrangements: Dr. Plott will receive standard compensation and equity awards available to non-employee directors, as detailed in the Company's 2026 Annual Report on Form 10-K. He will also enter into a standard indemnification agreement covering expenses, judgments, fines, and settlement amounts arising from his service.
Risks and Contingencies: The filing states there are no current or proposed transactions between the Company and Dr. Plott or his immediate family requiring disclosure under Item 404(a) of Regulation S-K. No other risks or unusual items were disclosed in this specific filing.
Investor Verification Checklist
- Verify Dr. R. Todd Plott's specific compensation package and equity grant details in the Company's most recent Form 10-K.
- Confirm the total number of Board seats and the composition of the Governance Committee following this appointment.
- Review the press release attached as Exhibit 99.1 for additional context on the strategic rationale for the appointment.